Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 9/20 | 0.32 |
| ▸ | HTR5A | P47898 | 3/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498121 | 0.87 | HTR2C (0.41) | BRD4CREBBPCTSSHTR5ACALCRL | |
| Hydrochloric Acid SCHEMBL11160630 | 0.86 | HTR2C (0.40) | BRD4CREBBPHTR5ACALCRLALDH1A1 | |
| Hydrochloric Acid SCHEMBL11097882 | 0.86 | HTR2C (0.40) | BRD4CREBBPHTR5ACALCRLALDH1A1 | |
| SCHEMBL14410233 | 0.82 | PARP1 (0.40) | BRD4CREBBPCTSSCALCRL | |
| SCHEMBL3279615 | 0.76 | BRD4 (0.50) | BRD4CREBBPCTSSCALCRL | |
| SCHEMBL11102413 | 0.76 | MAPK1 (0.48) | CALCRL | |
| SCHEMBL11102417 | 0.76 | MAPK1 (0.48) | CALCRL | |
| SCHEMBL5374765 | 0.75 | QPCT (0.40) | BRD4CREBBPCTSSHTR5ACALCRL | |
| SCHEMBL5377735 | 0.70 | OPRM1 (0.49) | CTSSCALCRL | |
| SCHEMBL11100446 | 0.70 | KCNH2 (0.33) | CALCRLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | claimed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | BRD4 3076/4885CREBBP 2215/4885CTSS 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.